1 active not recruiting, 1 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Low Dose Bevacizumab: new trials by email Literature Review of Low Dose Bevacizumab trials Research Report on Low Dose Bevacizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM Nivolumab, Standard Dose Bevacizumab, Low Dose Bevacizumab - Glioblastoma | Phase 2 | Active not recruiting | David Peereboom | 90 | 2018-05-21 | 2025-02-28 |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) Standard Dose Bevacizumab, Low Dose Bevacizumab, Lomustine - Brain Cancer, Glioblastoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 83 | 2010-01-01 | 2020-03-17 |
Glioblastoma (2) · Brain Neoplasms (1)
David Peereboom (1) · M.D. Anderson Cancer Center (1)
United States (2)
David Peereboom, MD (1) · John DeGroot, MD (1)